Codexis (CDXS) Projected to Post Earnings on Thursday

Codexis (NASDAQ:CDXS) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Codexis to post earnings of $0.01 per share and revenue of $35.8340 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Codexis Trading Down 8.5%

CDXS stock opened at $1.07 on Tuesday. Codexis has a 52-week low of $1.05 and a 52-week high of $4.30. The company has a quick ratio of 4.02, a current ratio of 4.12 and a debt-to-equity ratio of 1.03. The firm has a market cap of $96.64 million, a P/E ratio of -1.41 and a beta of 2.47. The company’s 50-day simple moving average is $1.50 and its 200-day simple moving average is $2.03.

Hedge Funds Weigh In On Codexis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Codexis by 41.8% during the fourth quarter. Invesco Ltd. now owns 174,590 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 51,454 shares in the last quarter. XTX Topco Ltd boosted its stake in Codexis by 330.9% during the 4th quarter. XTX Topco Ltd now owns 74,558 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 57,254 shares during the last quarter. Quadrature Capital Ltd grew its holdings in shares of Codexis by 102.2% during the fourth quarter. Quadrature Capital Ltd now owns 54,435 shares of the biotechnology company’s stock worth $89,000 after buying an additional 27,509 shares in the last quarter. Bridgeway Capital Management LLC raised its position in shares of Codexis by 49.6% in the fourth quarter. Bridgeway Capital Management LLC now owns 150,908 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 50,000 shares during the last quarter. Finally, Guggenheim Capital LLC purchased a new position in shares of Codexis in the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Wall Street Analysts Forecast Growth

CDXS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Codexis in a research report on Wednesday, January 21st. Wall Street Zen downgraded Codexis from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Codexis has an average rating of “Sell”.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.